> Details

Gozlan, Yael; Bucris, Efrat; Shirazi, Rachel; Rakovsky, Avia; Ben-Ari, Ziv; Davidov, Yana; Veizman, Ella; Saadi, Tarek; Braun, Marius; Cohen-Naftaly, Michal; Shlomai, Amir; Shibolet, Oren; Zigmond, Ehud; Katchman, Helena; Menachem, Yoram; Safadi, Rifaat; Galun, Eitan; Zuckerman, Eli; Nimer, Assy; Hazzan, Rawi; Maor, Yaakov; Saif, Abu Moch; Etzion, Ohad; Lurie, Yoav; [...]

High Frequency of Multiclass HCV Resistance-Associated Mutations in Patients Failing Direct-Acting Antivirals: Real-Life Data

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: High Frequency of Multiclass HCV Resistance-Associated Mutations in Patients Failing Direct-Acting Antivirals: Real-Life Data
  • Contributor: Gozlan, Yael; Bucris, Efrat; Shirazi, Rachel; Rakovsky, Avia; Ben-Ari, Ziv; Davidov, Yana; Veizman, Ella; Saadi, Tarek; Braun, Marius; Cohen-Naftaly, Michal; Shlomai, Amir; Shibolet, Oren; Zigmond, Ehud; Katchman, Helena; Menachem, Yoram; Safadi, Rifaat; Galun, Eitan; Zuckerman, Eli; Nimer, Assy; Hazzan, Rawi; Maor, Yaakov; Saif, Abu Moch; Etzion, Ohad; Lurie, Yoav; [...]
  • Published: SAGE Publications, 2019
  • Published in: Antiviral Therapy, 24 (2019) 3, Seite 221-228
  • Language: English
  • DOI: 10.3851/imp3301
  • ISSN: 1359-6535; 2040-2058
  • Origination:
  • Footnote:
  • Description: Background Direct-acting antiviral (DAA) therapy has dramatically increased sustained virological response rates in HCV-infected patients. However, resistance-associated substitutions (RAS) interfering with NS3- and NS5A-targeted therapy, still emerge. This real-life study analysed the type and frequency of RAS in rare cases of patients failing DAA regimens in 12 clinical centres in Israel. Methods Blood samples and clinical data from 49 patients who failed various DAAs were collected. RAS identified in the NS3 and NS5A regions by population (Sanger) and next-generation sequencing (NGS) were compared by treatment regimen and HCV subtypes. Results The majority (71.4%, 35/49) of patients were infected with the genotype (GT)1b strain, while 12.2% (6/49) carried GT1a and 14.3% GT3a/b (7), GT4a (1) and GT1b/GT3a. RAS were identified in 85.7% (42/49) of failures, of which 90.5% (38/42) were clinically relevant RAS (known to be associated with a specific GT and DAA in patients failing therapy or those with more than twofold change in in vitro replicon assays). The most abundant RAS were 168A/E/Q/G/N/V (32.6%, 16/49) identified in NS3, and 93H/N (61.2%, 30/49), 31I/M/V (34.7%, 17/49) and 30R/H/K (12.2%, 6/49), identified in NS5A. Significantly more clinically relevant RAS were identified in NS5A (82.2%, 37/45) than in NS3 (35.7%, 10/28; P<0.01). While RAS were identified in all GT1a, GT3b and GT4a failures (100%, 10/10), only 71.8% (28/39) of GT1b or GT3a failures had RAS ( P=0.09). In four cases, NGS identified additional clinically relevant RAS and in one patient, NGS deciphered coexistence of GT3a and GT1b infections. Conclusions Our findings, together with additional real-life data, will contribute to the optimization of retreatment in DAA failure, when cost-related and suboptimal regimens must be employed.
  • Access State: Open Access